Schoen Klinik Group, Germany’s fourth-largest family-run hospital, is exiting the UK market, following a portfolio reconsideration. With this exit, Schoen Klinik will now focus primarily on its core market, Germany.
Archives
Navigating the global pharma order in 2026 —in conversation with ING’s Stephen Farrelly and Diederik Stadig
Ahead of the HBI 2026 session ‘The new global pharma order: Trump, China and Europe's uncertain future’, HBI spoke to Stephen Farrelly, Managing Director, Global Lead Healthcare & Pharma at ING and Diederik Stadig, Senior Economist, Healthcare & Pharma at ING on what the future holds for pharma investment and strategy, from regulatory risks and European biopharma's structural challenges to the evolving role of CDMOs, CROs, and the role of private equity.
March 18, 2026
Lone Star buys Lonza’s CHI division for ~$3 billion
Private equity firm Lone Star Funds has acquired the Capsules & Health Ingredients (CHI) division of Swiss Contract Development and Manufacturing Organisation (CDMO) Lonza Group for an enterprise value of CHF 2.3 billion (~$3 billion). Headquartered in Basel, Switzerland, the CHI business manufactures capsules used to deliver medicines and dietary supplements. It operates across the Americas, Europe, and the Asia Pacific.
March 12, 2026
Verdane exits Omilon to Nexus AG
Private equity firm Verdane has sold Scandinavian tech company Omilon to private equity firm TA Associates backed-German health technology company, Nexus AG. Omilon provides AI-powered, speech-recognition, and voice-driven clinical documentation software.
March 11, 2026
Nordic Capital backed Sensio buys ISECO
European caretech company Sensio, backed by private equity firm Nordic Capital, has acquired ISECO, a caretech provider in Spain and Portugal.
ISECO operates in the Iberian care market, providing nurse call and workflow solutions for care operators.
March 11, 2026
Axcel buys Sangro Medical Service from Nordic Capital backed GHD Group
Nordic private equity firm Axcel has acquired Sangro Medical Service, a distributor and logistics provider in the German homecare market, in a carve-out deal from Nordic Capital-backed GHD GesundHeits GmbH, Germany's largest outpatient homecare provider.
March 11, 2026
Blackstone explores A$1 billion sale for Australia’s largest Phase 1 CRO Nucleus Network
American private equity firm Blackstone is exploring the sale of Nucleus Network, Australia’s largest Contract Research Organisation (CRO), with a valuation exceeding A$1 billion (~US$711.6 million). HBI understands that the private equity firm is indeed considering the sale.
March 11, 2026
India’s Zenex Animal Health buys Netherlands-based VievePharm
Zenex Animal Health, an animal health company based in western India and backed by private equity firm Multiples PE, has bought Netherlands-based VievePharm, which specialises in natural animal health and nutrition products.
March 6, 2026
GI Partners buys Charles River CDMO
American private equity firm GI Partners has agreed to acquire the contract development and manufacturing organisation (CDMO) and cell solutions businesses of Charles River Laboratories as part of a broader portfolio reshuffle by the global contract research organisation (CRO).
March 5, 2026
FutureLife Group buys UK-based fertility clinic Herts & Essex Fertility Centre
FutureLife Group, a pan-European provider of IVF and genetics services co-owned by Luxembourg-based private equity firm CVC Capital Partners and Central Europe-based Hartenberg Holding, has acquired UK-based IVF clinic Herts & Essex Fertility Centre.
March 5, 2026
EQT drops takeover bid for Oxford Biomedica
Swedish private equity firm EQT has confirmed its intention to drop the takeover bid for UK-based Contract Development Manufacturing Organisation (CDMO) Oxford Biomedica (OXB).
March 5, 2026
Australian CRO SSR invests in Singapore’s Expecto Health Science
Southern Star Research (SSR), an Australian clinical research organisation (CRO) backed by private equity firm Quadrant, has invested growth capital in Singapore-headquartered CRO Expecto Health Science.
With this investment, the two CROs will form a strategic partnership to facilitate transition for sponsors from early-phase studies in Australia and New Zealand into late-phase clinical development across key Asian markets.
